Patient-Friendly Explanation

Fetuin-A is a protein made mainly in the liver and released into the bloodstream. Levels tend to be higher when fat builds up in the liver, and high levels make the body respond less well to insulin, which can make blood sugar harder to control and weight loss harder to achieve.

Clinical Definition

Fetuin-A (alpha-2-HS-glycoprotein, AHSG) is a hepatocyte-secreted glycoprotein that inhibits insulin-receptor tyrosine kinase activity and acts as an endogenous ligand for TLR4, promoting adipose-tissue inflammation and insulin resistance. Circulating levels rise with hepatic steatosis and visceral adiposity and correlate with incident type 2 diabetes and cardiovascular risk; levels fall with weight loss, improved liver fat and metformin therapy. It also acts as a circulating inhibitor of ectopic calcification.

Why It Matters

Fetuin-A explains part of the pathway from a fatty liver to diabetes, which is why liver fat is treated as a metabolic problem rather than an incidental scan finding. NuLifeCare Singapore tracks liver enzymes, waist circumference and glycaemic markers alongside weight, because a falling fetuin-A pattern usually mirrors improving insulin sensitivity.